3-(3,5-difluorophenyl)aniline | 866108-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3,5-difluorophenyl)aniline
• 英文别名: 3',5'-Difluoro-biphenyl-3-amine
• CAS: 866108-74-9
• 化学式: C₁₂H₉F₂N
• 分子量: 205.207
• InChiKey: ZHFWIDMOBAWKST-UHFFFAOYSA-N

物化性质

• 沸点：
  336.9±32.0 °C(Predicted)
• 密度：
  1.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3,5-difluorophenyl)aniline 在 三甲基溴硅烷 作用下， 以 乙腈 为溶剂， 反应 20.0h， 生成 [(3',5'-Difluoro-biphenyl-3-ylamino)-phosphono-methyl]-phosphonic acid
  参考文献：
  名称：

  Bisphosphonate Inhibition of the Exopolyphosphatase Activity of the Trypanosoma brucei Soluble Vacuolar Pyrophosphatase

  摘要：

  Trypanosoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar pyrophosphatase, TbVSP1, not present in humans, which is essential for the growth of bloodstream forms in their mammalian host. Here, we report the inhibition of a recombinant TbVSP1 expressed in Escherichia coli by a panel of 81 bisphosphonates. The IC50 values were found to vary from similar to 2 to 850 mu M. We then used 3D QSAR (comparative molecular field and comparative molecular similarity index; CoMFA and CoMSIA) methods to analyze the enzyme inhibition results. The R-2 values for the experimental versus the QSAR-predicted activities were 0.78 or 0.61 for CoMFA and 0.79 or 0.68 for CoMSIA, for two different alignments. The root-mean-square (rms) pIC(50) error for the best CoMFA model was 0.41 for five test sets of five activity predictions, which translates to a factor of similar to 2.6 error in IC50 prediction. For CoMSIA, the rms pIC(50) error and error factors were 0.35 and 2.2, respectively. In general, the most active compounds contained both a single aromatic ring and a hydrogen bond donor feature. Thirteen of the more potent compounds were then tested in vivo in a mouse model of T. brucei infection. The most active compound in vivo provided a 40% protection from death with no apparent side effects, suggesting that further development of such compounds may be of interest.

  DOI：

  10.1021/jm058220g
• 作为产物：
  描述：

  3,5-二氟苯硼酸 在 盐酸 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 甲苯 为溶剂， 反应 10.0h， 生成 3-(3,5-difluorophenyl)aniline
  参考文献：
  名称：

  Bisphosphonate Inhibition of the Exopolyphosphatase Activity of the Trypanosoma brucei Soluble Vacuolar Pyrophosphatase

  摘要：

  Trypanosoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar pyrophosphatase, TbVSP1, not present in humans, which is essential for the growth of bloodstream forms in their mammalian host. Here, we report the inhibition of a recombinant TbVSP1 expressed in Escherichia coli by a panel of 81 bisphosphonates. The IC50 values were found to vary from similar to 2 to 850 mu M. We then used 3D QSAR (comparative molecular field and comparative molecular similarity index; CoMFA and CoMSIA) methods to analyze the enzyme inhibition results. The R-2 values for the experimental versus the QSAR-predicted activities were 0.78 or 0.61 for CoMFA and 0.79 or 0.68 for CoMSIA, for two different alignments. The root-mean-square (rms) pIC(50) error for the best CoMFA model was 0.41 for five test sets of five activity predictions, which translates to a factor of similar to 2.6 error in IC50 prediction. For CoMSIA, the rms pIC(50) error and error factors were 0.35 and 2.2, respectively. In general, the most active compounds contained both a single aromatic ring and a hydrogen bond donor feature. Thirteen of the more potent compounds were then tested in vivo in a mouse model of T. brucei infection. The most active compound in vivo provided a 40% protection from death with no apparent side effects, suggesting that further development of such compounds may be of interest.

  DOI：

  10.1021/jm058220g

文献信息

• [EN] ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7<br/>[FR] ACTIVATEURS DE PROCASPASES EFFECTRICES 3, 6 ET 7
  申请人：UNIV CALIFORNIA

  公开号：WO2009089508A1

  公开（公告）日：2009-07-16

  The present invention provides compounds as activators of procaspases 3, 6 and/or 7 and related derivatives, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. In one aspect, the compounds are useful for treating cancers and neoplastic diseases.

  本发明提供了作为procaspases 3、6和/或7的激活剂以及相关衍生物、其制药组合物、使用它们的方法以及制备这些化合物的方法。在一个方面，这些化合物对于治疗癌症和肿瘤性疾病是有用的。
• Activators of executioner procaspases 3, 6 and 7
  申请人：Wells Jim

  公开号：US08642788B2

  公开（公告）日：2014-02-04

  The present invention provides compounds as activators of procaspases 3, 6 and/or 7 and related derivatives, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. In one aspect, the compounds are useful for treating cancers and neoplastic diseases.

  本发明提供的化合物可作为procaspases 3、6和/或7的激活剂及相关衍生物、其制药组合物、使用它们的方法以及制备这些化合物的方法。在一个方面，这些化合物可用于治疗癌症和肿瘤性疾病。
• ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7
  申请人：Wells Jim

  公开号：US20110021522A1

  公开（公告）日：2011-01-27

  The present invention provides compounds as activators of procaspases 3, 6 and/or 7 and related derivatives, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. In one aspect, the compounds are useful for treating cancers and neoplastic diseases.

  本发明提供了化合物作为procaspases 3、6和/或7的激活剂及其相关衍生物，其制药组合物，它们的使用方法，以及这些化合物的制备方法。在一个方面，这些化合物对于治疗癌症和肿瘤性疾病是有用的。
• TETRAHYDRO-NAPHTHALENE DERIVATIVES
  申请人：Bayer HealthCare AG

  公开号：EP1569896B1

  公开（公告）日：2007-08-15
• OXADIAZOLOPYRAZINES AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL UNCOUPLERS
  申请人：Virginia Tech Intellectual Properties, Inc.

  公开号：EP3781572A1

  公开（公告）日：2021-02-24